- Home
- HIO vs ATXS Comparison
HIO vs ATXS Comparison
Compare HIO & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIO
- ATXS
- Stock Information
- Founded
- HIO 1993
- ATXS 2008
- Country
- HIO United States
- ATXS United States
- Employees
- HIO N/A
- ATXS N/A
- Industry
- HIO Finance/Investors Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- HIO Finance
- ATXS Health Care
- Exchange
- HIO Nasdaq
- ATXS Nasdaq
- Market Cap
- HIO 379.0M
- ATXS 401.2M
- IPO Year
- HIO N/A
- ATXS 2015
- Fundamental
- Price
- HIO $4.13
- ATXS $6.19
- Analyst Decision
- HIO
- ATXS Strong Buy
- Analyst Count
- HIO 0
- ATXS 6
- Target Price
- HIO N/A
- ATXS $25.67
- AVG Volume (30 Days)
- HIO 305.3K
- ATXS 226.5K
- Earning Date
- HIO 01-01-0001
- ATXS 03-14-2025
- Dividend Yield
- HIO 10.33%
- ATXS N/A
- EPS Growth
- HIO N/A
- ATXS N/A
- EPS
- HIO N/A
- ATXS N/A
- Revenue
- HIO N/A
- ATXS N/A
- Revenue This Year
- HIO N/A
- ATXS N/A
- Revenue Next Year
- HIO N/A
- ATXS N/A
- P/E Ratio
- HIO N/A
- ATXS N/A
- Revenue Growth
- HIO N/A
- ATXS N/A
- 52 Week Low
- HIO $3.52
- ATXS $5.84
- 52 Week High
- HIO $4.03
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- HIO 70.93
- ATXS 32.55
- Support Level
- HIO $4.03
- ATXS $5.84
- Resistance Level
- HIO $4.11
- ATXS $6.88
- Average True Range (ATR)
- HIO 0.04
- ATXS 0.33
- MACD
- HIO 0.01
- ATXS 0.02
- Stochastic Oscillator
- HIO 86.11
- ATXS 23.97
About HIO Western Asset High Income Opportunity Fund Inc.
Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests in various sectors such as auto components, hotels, restaurants and leisure, household durables, food & staples, energy, banks, capital markets, consumer finance, insurance, pharmaceuticals, aerospace and defense, and others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.